BSR statement in support of the Lancet Report on NICE
BSR statement on the sequential use of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis
Document Actions
The British Society for Rheumatology (BSR) is extremely disappointed that the National Institute for Health and Clinical Excellence (NICE) has released an Appraisal Consultation Document not allowing patients access to an alternative anti-TNF if they have experienced an inadequate response with a first anti-TNF.
Dr Deborah Bax, BSR President said; “We are very disappointed that NICE has taken this decision, particularly as there is a large and growing data base indicating successful treatment with a second anti-TNF. We strongly believe the effect of treatment with anti-TNF for many patients with rheumatoid arthritis is substantial. We will continue to press NICE to allow this treatment to be used more widely in the disease”.
For further information contact:
Katy Lewis
(020) 7842 0919